XORTX Therapeutics Inc (XRTX.V) expected to post a loss of 33 cents a share - Earnings Preview

Reuters
2025.03.28 20:38
portai
I'm PortAI, I can summarize articles.

XORTX Therapeutics Inc (XRTX.V) is anticipated to report a loss of 33 cents per share for the period ending December 31, 2024, with results expected on March 31. The sole analyst rating is a "buy," and the median 12-month price target is $14.00, significantly higher than the last closing price of $0.96. The mean earnings estimate has remained unchanged over the past three months.

  • XORTX Therapeutics Inc (XRTX.V) is expected to report results on March 31 (estimated) for the period ending December 31 2024

  • ​LSEG’s mean analyst estimate for XORTX Therapeutics Inc is for a loss of 33 cents per share.

  • The one available analyst rating on the shares is “buy”.

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street’s median 12-month price target for XORTX Therapeutics Inc is $14.00​, above​ its last closing price of $0.96. ​​​ This summary was machine generated March 28 at 20:38 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.